The short version of LC-MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-25 and is reviewed periodically as new material appears.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Tyrosine sulfation is a posttranslational modification in which a tyrosine residue of a protein is sulfated by a tyrosylprotein sulfotransferase (TPST) typically in the Golgi apparatus. Secreted proteins and extracellular parts of membrane proteins that pass through the Golgi apparatus may be sulfated. Sulfation occurs in animals and plants but not in prokaryotes or in yeasts. Sulfation sites are tyrosine residues exposed on the surface of the protein typically surrounded by acidic residues. The function of sulfation remains uncertain.
In September 2015, chairman Russ Withers and chief executive Warren Wilmot announced they were resigning from the company. Deputy chairman Michael Smith replaced Withers, while Bob Baily was appointed as interim chief executive. In December 2015, Stewart Levitt of law firm Levitt Robinson Solicitors, who featured prominently in the Four Corners program, announced a potential class action lawsuit against 7-Eleven head office on behalf of franchisees who had allegedly been lured into signing on with 7-Eleven by false representations. This announcement was made on the same day as a Court finding describing Levvit Robinson's "hellish bullying" of Dr Brendan French, miring the action in controversy. Also on that day, 7-Eleven offered to pay "the first $25 million of back-pay claims brought by current and former workers. Franchisees would then pay the next $5 million and any payments after that would be split 50-50 between head office and franchisees." Fels "described the $25 million offer from head office as a 'significant step forward'" but added that his panel's investigation would not be effected. 7-Eleven ultimately paid more than $173 million for "systematic wage theft" to workers employed between 2015 and 2020. Levvit Robinson was forced to retract misleading statements made in advertising to 7-Eleven franchisees in June 2018 by the Federal Court of Australia. This occurred only months after Levvit Robinson launched a new class action against 7-Eleven that included the ANZ Bank despite banks having stopped loans to 7-Eleven franchisees in 2015.
Once all the eggs are secured in the nest, the pair will spawn again. If more than one female is present in the breeding tank, the male may spawn with all of them. The spawning sessions will continue for two to four hours, and produce between 300 and 800 eggs. Dwarf gouramis have a fecundity of about 600 eggs.[1] Upon completion, the male will place a fine layer of bubbles beneath the eggs, assuring that they remain in the bubble nest. The male will protect the eggs and fry. In 12 to 24 hours the fry will hatch, and continue developing within the protection of the bubble nest. After three days they are sufficiently developed to be free swimming and leave the nest. When the fry are two to three days old the male should also be removed or he may consume the young. After spawning the female should be moved to a different tank. The male will now take sole responsibility for the eggs, aggressively defending the nest and surrounding territory. When first hatched, the tiny fry should be fed infusoria, and later, brine shrimp and finely ground flakes. Freeze-dried tablets may also be fed to older fry.
=== Other === Other physical integration methods (spray or spin coating, blending, and vacuum filtration) have been developed for paper electronics, but have yet to be implemented in paper-based microfluidic devices.
=== Denise Oldroyd === Denise Oldroyd (Fiona Button) is Yasmin's lawyer, and sister of her ex-boyfriend Seb. Denise represents Yasmin following the publication of her father's historic embezzlement from the family publishing company. She also has a brief affair with Eric that begins after he joins her and Yasmin on a cocaine bender. When Hanani Publishing decides to pay off Charles' various legal settlements in exchange for making Yasmin the face of the scandal, Denise encourages Yasmin to go along with the deal to protect the victims of Charles' sexual abuse, but Yasmin decides to fight her father's company in court.
Sources: en.wikipedia.org
=== Thrombotic disease === Various kits have a 93 to 95% sensitivity (true positive rate). For hospitalized patients, one study found the specificity to be about 50% (related to false positive rate) in the diagnosis of thrombotic disease.
GoldSrc (pronounced "gold source", formerly the Half-Life Engine) is a proprietary game engine developed by Valve. At its core, GoldSrc is a heavily modified version of id Software's Quake engine. It made its debut in 1998 with Half-Life and powered future games developed by or with oversight from Valve, including Half-Life's expansions, Day of Defeat and games in the Counter-Strike series. GoldSrc was succeeded by the Source engine with the releases of Half-Life: Source, Half-Life 2, and Counter-Strike: Source in 2004.
==== Delta (δ) notation ==== Isotope ratios for a substance are often reported compared to a standard with known isotopic composition, and measurements of relative masses are always made in conjuncture with measuring a standard. For hydrogen, the Vienna Standard Mean Ocean Water standard is used which has an isotope ratio of 155.76±0.1 ppm. The delta value as compared to this standard is defined as:
During the process of DNA replication, errors occasionally occur in the polymerization of the second strand. These errors, called mutations, can affect the phenotype of an organism, especially if they occur within the protein coding sequence of a gene. Error rates are usually very low—1 error in every 10–100 million bases—due to the "proofreading" ability of DNA polymerases. Processes that increase the rate of changes in DNA are called mutagenic: mutagenic chemicals promote errors in DNA replication, often by interfering with the structure of base-pairing, while UV radiation induces mutations by causing damage to the DNA structure. Chemical damage to DNA occurs naturally as well and cells use DNA repair mechanisms to repair mismatches and breaks. The repair does not, however, always restore the original sequence. A particularly important source of DNA damages appears to be reactive oxygen species produced by cellular aerobic respiration, and these can lead to mutations.
When the text was disclosed in the British press, it generated a storm of anti-German feeling. In the baggage of the raiding column, to the embarrassment of Britain, the Boers found telegrams from Rhodes and other plotters in Johannesburg. Chamberlain had approved Rhodes' plans to send armed assistance in the case of a Johannesburg uprising, but he quickly moved to condemn the raid. Rhodes was censured at the Cape and London parliamentary inquiries, and forced to resign as Prime Minister and Chairman of the British South Africa Company. The Boer government handed their prisoners over to the British for trial. Jameson was tried in England, where the press and London society, inflamed by anti-Boer and anti-German feeling and in a frenzy of jingoism, treated him as a hero. Although sentenced to 15 months imprisonment, Jameson was rewarded by being named Prime Minister of the Cape Colony (1904–08) and ultimately anointed as one of the founders of the Union of South Africa. For conspiring with Jameson, the uitlander members of the Reform Committee (Transvaal) were tried in the Transvaal courts and found guilty of treason. The four leaders were sentenced to death, but this was commuted to 15 years' imprisonment. In 1896, the other members of the committee were released on payment of £2,000 in fines, all paid by Rhodes. One Reform Committee member, Frederick Gray, committed suicide while in Pretoria jail. His death was a factor in softening the Transvaal government's attitude to the surviving prisoners. Jan C. Smuts wrote, in 1906:
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.